Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 137

Sort by

Sort Order Select

Journal Articles

Progressive Down Regulation of JAK-STAT, Cell Cycle, and ABC Transporter Genes in CD34+/Lin- Cells of Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients at Diagnosis Vs. 12 Months of Nilotinib Treatment Vs. Healthy Subjects

Blood (2019) 134 (Supplement_1): 5034.

https://doi.org/10.1182/blood-2019-125595

Published: 2019

Journal Articles

Transmembrane Receptors, Cytoskeleton and Cell Cycle Genes Were Progressively Deregulated in the Bone Marrow CD19+ and CD138+ Cells of Patientswwith Waldenstrom's Macroglolubinemia (WM) Vs. Subjects with IgM Monoclonal Gammopathy of Undetermined Significance Igmmgus Vs. Healthy Subjects

Alessandra Trojani, Alessandra Tedeschi, MD, Annamaria Maria Frustaci, Marina Deodato, Luca Emanuele Bossi, Barbara Di Camillo, Marco Montillo, MD, Enrica Morra, Roberto Cairoli, MD

Blood (2019) 134 (Supplement_1): 5036.

https://doi.org/10.1182/blood-2019-125577

Published: 2019

Journal Articles

Nilotinib Deregulates Cell Cycle Checkpoints, ABC Transporters Genes and JAK-STAT Signaling Pathway of CD34+/Lin- Cells in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients after 12 Months of Treatment

Blood (2018) 132 (Supplement 1): 5122.

https://doi.org/10.1182/blood-2018-99-112188

Published: 2018

Journal Articles

Combining Imatinib-Following-Nilotinib Treatment in First Line Therapy for Chronic Phase Chronic Myeloid Leukemia. Update from the PhilosoPhi34 Study at 24 Months of Follow-up

Blood (2018) 132 (Supplement 1): 5435.

https://doi.org/10.1182/blood-2018-99-113496

Published: 2018

Journal Articles

Jak-2 and Nfkbia G ene Expression Play a Strategic Role in Chronic Myeloid Leukemia (CML) Molecular Response during Early Nilotinib Treatment: The PhilosoPhi34 Data

Blood (2018) 132 (Supplement 1): 5118.

https://doi.org/10.1182/blood-2018-99-113273

Published: 2018

Journal Articles

Preliminary Experience of Imatinib after Nilotinib in the First Line Treatment of Chronic Myeloid Leukemia

Blood (2017) 130 (Supplement 1): 2889.

https://doi.org/10.1182/blood.V130.Suppl_1.2889.2889

Published: 2017

Journal Articles

Gene Expression Profiling and Cellularity of Bone Marrow CD34+/Lin- Cells of Patients with Chronic-Phase Chronic Myeloid Leukemia at Diagnosis Vs. 12 Months of First-Line Nilotinib Treatment

Blood (2017) 130 (Supplement 1): 4973.

https://doi.org/10.1182/blood.V130.Suppl_1.4973.4973

Published: 2017

Journal Articles

The REL-Protocol PhilosoPhi34 - an Open Label, Single Arm, Phase II Study of Nilotinib 300 Mg BID in Newly Diagnosed Chronic Phase Chronic Myeloid Leukaemia (CML) Patients - Confirms Early Clearance of Bone Marrow CD34+/Lin-Ph+ Cells

Blood (2016) 128 (22): 3080.

https://doi.org/10.1182/blood.V128.22.3080.3080

Published: 2016

Journal Articles

Transcriptome Analysis Identified Significant Differences in Gene Expression Variability Between WM and IgM-MGUS BM B Cell Clones

Alessandra Trojani, Milena Lodola, Alessandra Tedeschi, Antonino Greco, Barbara Di Camillo, Tiziana Sanavia, Anna Maria Frustaci, Maddalena Mazzucchelli, Chiara Villa, Daniela Boselli, Enrica Morra, MD, Roberto Cairoli, MD

Blood (2016) 128 (22): 5089.

https://doi.org/10.1182/blood.V128.22.5089.5089

Published: 2016

Journal Articles

Treatment recommendations from the Eighth International Workshop on Waldenström’s Macroglobulinemia

Véronique Leblond, Efstathios Kastritis, Ranjana Advani, Stephen M. Ansell, Christian Buske, Jorge J. Castillo, Ramón García-Sanz, Morie Gertz, Eva Kimby, Charalampia Kyriakou, Giampaolo Merlini, Monique C. Minnema, Pierre Morel, Enrica Morra, Mathias Rummel, Ashutosh Wechalekar, Christopher J. Patterson, Steven P. Treon, Meletios A. Dimopoulos

Blood (2016) 128 (10): 1321–1328.

https://doi.org/10.1182/blood-2016-04-711234

Published: 2016

Journal Articles

Long Term Toxicity and Follow-up of Waldenstrom´s Macroglobulinemia Patients after Salvage Treatment with Fludarabine Cyclophosphamide Rituximab or Bendamustine and Rituximab

Blood (2015) 126 (23): 3958.

https://doi.org/10.1182/blood.V126.23.3958.3958

Published: 2015

Journal Articles

GEP Analyses of Bone Marrow CD34+/Lin- Cells of Chronic Phase CML Patients at Diagnosis Identified Different Sets of Genes Associated to the Molecular Response after 3 and 6 Months of First-Line Nilotinib Treatment

Alessandra Trojani, PhD, Ester Pungolino, MD, Milena Lodola, Barbara Di Camillo, Mariella D'Adda, MD, Alessandra Perego, MD, Mauro Turrini, MD, Chiara Elena, MD, Alessandra Iurlo, MD PhD, Cristina Buccelli, Simona Malato, MD, Francesco Spina, MD, Maria Luisa Latargia, Francesco Lanza, Sergio Pauli, MD, Michela Anghilieri, MD, Maria Cristina Carraro, Enrica Morra, MD, Roberto Cairoli, MD

Blood (2015) 126 (23): 3645.

https://doi.org/10.1182/blood.V126.23.3645.3645

Published: 2015

Journal Articles

The Clonal Architecture of CXCR4mutations in Waldenstrom's Macroglobulinemia Shows Highly Variable Subclonal Distribution, and Multiple Mutations within Individual Patients Indicative of Targeted Genomic Instability

Blood (2015) 126 (23): 1486.

https://doi.org/10.1182/blood.V126.23.1486.1486

Published: 2015

Journal Articles

REL-Protocol PhilosoPhi34: An Open Label, Single Arm, Phase II Study of Nilotinib 300 Mg BID in Newly Diagnosed Chronic Phase Chronic Myeloid Leukaemia Patients, to Study the Disappearance of CD34+/Lin-Ph+ Cells from Bone Marrow during Treatment. Preliminary Data

Blood (2015) 126 (23): 1597.

https://doi.org/10.1182/blood.V126.23.1597.1597

Published: 2015

Journal Articles

Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis

Nicolaus Kröger, Toni Giorgino, Bart L. Scott, Markus Ditschkowski, Haefaa Alchalby, Francisco Cervantes, Alessandro Vannucchi, Mario Cazzola, Enrica Morra, Tatjana Zabelina, Margherita Maffioli, Arturo Pereira, Dietrich Beelen, H. Joachim Deeg, Francesco Passamonti

Blood (2015) 125 (21): 3347–3350.

https://doi.org/10.1182/blood-2014-10-608315

Published: 2015

Journal Articles

Low Risk IPSS/DIPSS Primary Myelofibrosis: Identification of Patients with Higher Risk of Progression

Margherita Maffioli, MD, Francisco Cervantes, MD PhD, Mario Cazzola, MD, Alessandro M. Vannucchi, MD, Enrica Morra, Domenica Caramazza, MD PhD, Barbara Mora, MD, Toni Giorgino, PhD, Francesco Passamonti, MD

Blood (2014) 124 (21): 3187.

https://doi.org/10.1182/blood.V124.21.3187.3187

Published: 2014

Journal Articles

Bendamustine and Rituximab Combination Is Safe and Effective As Salvage Regimen in Waldenstrom's Macroglobulinemia

Blood (2014) 124 (21): 3072.

https://doi.org/10.1182/blood.V124.21.3072.3072

Published: 2014

Journal Articles

Danazol Treatment in Lower Risk MDS Patient with Severe Thrombocytopenia: A Monocentric Experience

Alfredo Molteni, Marta Riva, Emanuele Ravano, MD, Rosa Greco, Enrica Morra

Blood (2014) 124 (21): 5615.

https://doi.org/10.1182/blood.V124.21.5615.5615

Published: 2014

Journal Articles

Transcriptome-Wide Analysis of Bone Marrow CD19+ Cells As Well As Bone Marrow B Cell Clones of Waldenström's Macroglobulinemia (WM) Vs. IgM Monoclonal Gammopathy of Undetermined Significance (IgM-MGUS)

Alessandra Trojani, Antonino Greco, Alessandra Tedeschi, MD, Milena Lodola, Barbara Di Camillo, Anna Maria Frustaci, Enrica Morra

Blood (2014) 124 (21): 5176.

https://doi.org/10.1182/blood.V124.21.5176.5176

Published: 2014

Journal Articles

Gene Expression Profiling of CD34+/Lin- Cells of Patients with Chronic Myeloid Leukemia at Diagnosis and after 12 Months of Nilotinib

Alessandra Trojani, Milena Lodola, Barbara Di Camillo, Giuseppe Rossi, MD, Adele Capucci, Alessandra Perego, Enrico Maria Pogliani, MD, Ester Orlandi, MD, Alessandra Iurlo, MD PhD, Simona Malato, Paolo Corradini, MD, Roberto Cairoli, Marco Bregni, Salvatore Artale, Enrica Morra, Ester Pungolino, MD

Blood (2014) 124 (21): 5177.

https://doi.org/10.1182/blood.V124.21.5177.5177

Published: 2014

NARROW

Progressive Down Regulation of JAK-STAT, Cell Cycle, and ABC Transporter Genes in CD34+/Lin- Cells of Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients at Diagnosis Vs. 12 Months of Nilotinib Treatment Vs. Healthy Subjects

Transmembrane Receptors, Cytoskeleton and Cell Cycle Genes Were Progressively Deregulated in the Bone Marrow CD19+ and CD138+ Cells of Patientswwith Waldenstrom's Macroglolubinemia (WM) Vs. Subjects with IgM Monoclonal Gammopathy of Undetermined Significance Igmmgus Vs. Healthy Subjects

Nilotinib Deregulates Cell Cycle Checkpoints, ABC Transporters Genes and JAK-STAT Signaling Pathway of CD34+/Lin- Cells in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients after 12 Months of Treatment

Combining Imatinib-Following-Nilotinib Treatment in First Line Therapy for Chronic Phase Chronic Myeloid Leukemia. Update from the PhilosoPhi34 Study at 24 Months of Follow-up

Jak-2 and Nfkbia G ene Expression Play a Strategic Role in Chronic Myeloid Leukemia (CML) Molecular Response during Early Nilotinib Treatment: The PhilosoPhi34 Data

Preliminary Experience of Imatinib after Nilotinib in the First Line Treatment of Chronic Myeloid Leukemia

Gene Expression Profiling and Cellularity of Bone Marrow CD34+/Lin- Cells of Patients with Chronic-Phase Chronic Myeloid Leukemia at Diagnosis Vs. 12 Months of First-Line Nilotinib Treatment

The REL-Protocol PhilosoPhi34 - an Open Label, Single Arm, Phase II Study of Nilotinib 300 Mg BID in Newly Diagnosed Chronic Phase Chronic Myeloid Leukaemia (CML) Patients - Confirms Early Clearance of Bone Marrow CD34+/Lin-Ph+ Cells

Transcriptome Analysis Identified Significant Differences in Gene Expression Variability Between WM and IgM-MGUS BM B Cell Clones

Treatment recommendations from the Eighth International Workshop on Waldenström’s Macroglobulinemia

Long Term Toxicity and Follow-up of Waldenstrom´s Macroglobulinemia Patients after Salvage Treatment with Fludarabine Cyclophosphamide Rituximab or Bendamustine and Rituximab

GEP Analyses of Bone Marrow CD34+/Lin- Cells of Chronic Phase CML Patients at Diagnosis Identified Different Sets of Genes Associated to the Molecular Response after 3 and 6 Months of First-Line Nilotinib Treatment

The Clonal Architecture of CXCR4mutations in Waldenstrom's Macroglobulinemia Shows Highly Variable Subclonal Distribution, and Multiple Mutations within Individual Patients Indicative of Targeted Genomic Instability

REL-Protocol PhilosoPhi34: An Open Label, Single Arm, Phase II Study of Nilotinib 300 Mg BID in Newly Diagnosed Chronic Phase Chronic Myeloid Leukaemia Patients, to Study the Disappearance of CD34+/Lin-Ph+ Cells from Bone Marrow during Treatment. Preliminary Data

Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis

Low Risk IPSS/DIPSS Primary Myelofibrosis: Identification of Patients with Higher Risk of Progression

Bendamustine and Rituximab Combination Is Safe and Effective As Salvage Regimen in Waldenstrom's Macroglobulinemia

Danazol Treatment in Lower Risk MDS Patient with Severe Thrombocytopenia: A Monocentric Experience

Transcriptome-Wide Analysis of Bone Marrow CD19+ Cells As Well As Bone Marrow B Cell Clones of Waldenström's Macroglobulinemia (WM) Vs. IgM Monoclonal Gammopathy of Undetermined Significance (IgM-MGUS)

Gene Expression Profiling of CD34+/Lin- Cells of Patients with Chronic Myeloid Leukemia at Diagnosis and after 12 Months of Nilotinib

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only